8MV0 Stock Chart & Stats
€1.41
-€0.15(-8.67%)
At close: 4:00 PM EDT
€1.41
-€0.15(-8.67%)
Day’s Range― - ―
52-Week Range€1.10 - €10.80
Previous CloseN/A
Volume0.00
Average Volume (3M)30.00
Market Cap
€36.81M
Enterprise Value€66.16M
Total Cash (Recent Filing)€16.22M
Total Debt (Recent Filing)€17.55M
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Nov 30, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding22,667,843
10 Day Avg. Volume72
30 Day Avg. Volume30
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)3.75
Price to Sales (P/S)2.77
P/FCF Ratio-9.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.06Price Target Upside471.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.35
Revenue Forecast (FY)€37.71M
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth And Gross MarginRevenue has reached $35.5M TTM, up about 92% year over year, while gross margin is near 59%. This combination indicates meaningful product demand and attractive unit economics, giving BHST a stronger base to fund commercialization and pursue scale, even before profitability.
CDMO Expansion Into High-Value CompoundsThe first 20-ton fragrance agreement expands BHST beyond consumer supplements into contract manufacturing of high-value plant-derived compounds. Potential 2027–2028 revenue and a multi-year manufacturing opportunity could diversify revenue and create a platform for recurring production and royalties.
Improved Liquidity PositionThe substantial increase in cash and deposits improves near-term financial flexibility relative to the prior year. Greater liquidity can support CDMO capacity development, ongoing research, and commercialization while reducing immediate dependence on equity financing during the platform’s expansion.
Bears Say
Persistent Losses And Cash BurnBHST continues to consume cash while operating at a meaningful net loss, showing that revenue growth and gross margin have not yet translated into self-funded operations. Sustained burn may require financing or balance-sheet capacity, limiting flexibility until the business reaches break-even.
Lowered Revenue And EBITDA GuidanceThe reduced 2026 revenue outlook and wider expected EBITDA loss indicate that the transition toward CDMO investment is weakening near-term operating performance. This raises execution risk because management must fund capacity and growth initiatives while the core business remains below profitability.
Uncertain CDMO Contract EconomicsAlthough the fragrance agreement offers meaningful long-term potential, the absence of upfront payments and unresolved royalty terms leave the near-term economics uncertain. Delayed revenue recognition and an unsettled commercial structure could reduce cash support and make the opportunity harder to forecast.
BioHarvest Sciences News
8MV0 FAQ
What was BioHarvest Sciences’s price range in the past 12 months?
BioHarvest Sciences lowest stock price was €1.10 and its highest was €10.80 in the past 12 months.
What is BioHarvest Sciences’s market cap?
BioHarvest Sciences’s market cap is €36.81M.
When is BioHarvest Sciences’s upcoming earnings report date?
BioHarvest Sciences’s upcoming earnings report date is Nov 30, 2026 which is in 46 days.
How were BioHarvest Sciences’s earnings last quarter?
BioHarvest Sciences released its earnings results on Aug 11, 2026. The company reported -€0.152 earnings per share for the quarter, missing the consensus estimate of -€0.105 by -€0.046.
Is BioHarvest Sciences overvalued?
According to Wall Street analysts BioHarvest Sciences’s price is currently Undervalued.
Does BioHarvest Sciences pay dividends?
BioHarvest Sciences does not currently pay dividends.
What is BioHarvest Sciences’s EPS estimate?
BioHarvest Sciences’s EPS estimate is -0.12.
How many shares outstanding does BioHarvest Sciences have?
BioHarvest Sciences has 22,667,843 shares outstanding.
What happened to BioHarvest Sciences’s price movement after its last earnings report?
BioHarvest Sciences reported an EPS of -€0.152 in its last earnings report, missing expectations of -€0.105. Following the earnings report the stock price went down -25.455%.
Which hedge fund is a major shareholder of BioHarvest Sciences?
Currently, no hedge funds are holding shares in DE:8MV0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioHarvest Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€8.06 (471.47% Upside)
€8.06 (471.47% Upside)
Blogger Sentiment
Bullish
DE:8MV0 Sentiment 67%
Sector Average 64%
Sector Average 64%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-85.49%
12-Months-Change
Fundamentals
Return on Equity
-58.30%
Trailing 12-Months
Asset Growth
60.33%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
BioHarvest Sciences
BioHarvest Sciences Inc. is a biotechnology company that operates through two segments: Products and CDMO Services. The company has developed a botanical synthesis platform technology to grow plant cells with higher concentrations of active ingredients. It is involved in the research, development, manufacturing, and sale of science-based health and wellness nutraceutical solutions, as well as offering Contract Development and Manufacturing Operation (CDMO) services to third parties in the pharmaceutical, cosmeceutical, and nutrition industries.
8MV0 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced significant strategic progress and validation—most notably the major fragrance CDMO contract, stronger cash position, and government-backed technology grants—against near-term revenue guidance cuts, higher operating expenses, and continued adjusted EBITDA losses. Management is pivoting resources toward higher-margin CDMO opportunities and capacity build-out, accepting lower near-term product revenue (VINIA) in order to pursue longer-term profitability and scale. Key positives are the sizeable contract pipeline and material cash increase; key negatives are reduced 2026 top-line guidance and short-term profitability pressures stemming from reallocated marketing and development spend.View all DE:8MV0 earnings summaries8MV0 Stock 12 Month Forecast
Average Price Target
€8.06
▲(471.47% Upside)